Drugs / RN9101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07628595 | Jul 2026 → Dec 2027 expected | plasma cell myeloma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RN9101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07628595 ↗ |
| Route | Intravenous | “single intravenous infusion of RN9101 injection” NCT07628595 ↗ |
| Target | CD19 | “CD19/BCMA-targeted CAR” NCT07628595 ↗ |